(JHCB) John Hancock - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US47804J8181 • Corporate Bond
JHCB: Corporate Bonds, Investment-Grade Bank Loans, Cash Equivalents
The John Hancock Corporate Bond ETF (JHCB) is a fixed-income exchange-traded fund that primarily focuses on investing in corporate bonds. Under normal market conditions, the fund allocates at least 80% of its net assets to corporate bonds, which includes both investment-grade and high-yield securities. This strategy is designed to provide exposure to the corporate bond market while maintaining a diversified portfolio. The fund may also invest up to 20% of its net assets in investment-grade bank loans, including loan participations, and cash equivalents, which can help manage liquidity and credit risk. Additionally, JHCB may invest up to 10% of its total assets in securities denominated in foreign currencies, allowing for some exposure to international markets.
As a corporate bond ETF, JHCB is categorized under fixed income investments and is listed on the NYSE ARCA exchange. The fund is structured to provide investors with regular income through bond interest payments, while also offering the potential for capital appreciation. Corporate bond ETFs like JHCB are often used by investors seeking stable returns with lower volatility compared to equity investments. The funds moderate size, with assets under management (AUM) of $57.34 million, allows for efficient portfolio management while maintaining diversification across various corporate issuers.
Based on the provided data, JHCBs technical indicators suggest a stable performance. The funds last price of $21.36 is slightly above its 20-day simple moving average (SMA) of $21.21, indicating a short-term bullish trend. However, the 50-day SMA of $21.00 and the 200-day SMA of $20.91 suggest that the fund is in a longer-term consolidation phase. The Average True Range (ATR) of 0.10 indicates low volatility, which is typical for fixed-income ETFs. The average volume of 7,100 shares over the past 20 days reflects moderate trading activity, which is sufficient for most investors seeking liquidity.
Looking ahead, the 3-month forecast for JHCB is expected to remain stable, with potential price movements influenced by its moving averages and volatility metrics. The funds price is likely to fluctuate within a narrow range, bounded by support at the 200-day SMA ($20.91) and resistance at the recent high of $21.36. If the price breaks above the 20-day SMA, it could test the upper resistance level. Conversely, a break below the 50-day SMA could lead to a retest of the lower support level. Given the low ATR, volatility is expected to remain subdued, making JHCB a relatively stable investment option for income-focused investors.
Additional Sources for JHCB ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
JHCB ETF Overview
Market Cap in USD | 56m |
Category | Corporate Bond |
TER | 0.29% |
IPO / Inception | 2021-03-30 |
JHCB ETF Ratings
Growth Rating | 5.02 |
Fundamental | - |
Dividend Rating | 75.7 |
Rel. Strength | 4.76 |
Analysts | - |
Fair Price Momentum | 20.65 USD |
Fair Price DCF | - |
JHCB Dividends
Dividend Yield 12m | 5.25% |
Yield on Cost 5y | 5.17% |
Annual Growth 5y | 14.37% |
Payout Consistency | 100.0% |
JHCB Growth Ratios
Growth Correlation 3m | -29.4% |
Growth Correlation 12m | 52.5% |
Growth Correlation 5y | -16.5% |
CAGR 5y | -0.30% |
CAGR/Max DD 5y | -0.01 |
Sharpe Ratio 12m | 0.36 |
Alpha | 0.83 |
Beta | 0.024 |
Volatility | 8.59% |
Current Volume | 5.5k |
Average Volume 20d | 6.5k |
As of May 09, 2025, the stock is trading at USD 20.94 with a total of 5,469 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +2.23%, over three months by +0.22% and over the past year by +5.18%.
Neither. Based on ValueRay Analyses, John Hancock is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 5.02 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of JHCB as of May 2025 is 20.65. This means that JHCB is currently overvalued and has a potential downside of -1.38%.
John Hancock has no consensus analysts rating.
According to ValueRays Forecast Model, JHCB John Hancock will be worth about 22.3 in May 2026. The stock is currently trading at 20.94. This means that the stock has a potential upside of +6.49%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 22.3 | 6.5% |